Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XERS Xeris Pharmaceuticals Inc

Market Closed 12-12 16:00:00 EST

7.17

+0.16

+2.28%

盘后7.21

+0.04+0.56%

19:58 EST

High7.20	Low7.00	Vol1.72M
Open7.09	D1 Closing7.01	Amplitude2.85%
Mkt Cap1.19B	Tradable Cap1.14B	Total Shares165.92M
T/O12.28M	T/O Rate1.08%	Tradable Shares159.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"XERS","market":"US","secType":"STK","nameCN":"Xeris Pharmaceuticals Inc","latestPrice":7.17,"timestamp":1765573200000,"preClose":7.01,"halted":0,"volume":1722025,"hourTrading":{"tag":"盘后","latestPrice":7.21,"preClose":7.17,"latestTime":"19:58 EST","volume":371392,"amount":2662889.251,"timestamp":1765587482193},"delay":0,"floatShares":159000000,"shares":165924289,"eps":-0.10439,"marketStatus":"Market Closed","change":0.16,"latestTime":"12-12 16:00:00 EST","open":7.09,"high":7.2,"low":7,"amount":12278086.4667,"amplitude":0.028531,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.10439,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1529553600000,"exchange":"NASDAQ","adjPreClose":7.01,"preHourTrading":{"tag":"盘前","latestPrice":7.14,"preClose":7.01,"latestTime":"09:28 EST","volume":1401,"amount":10079.9894733,"timestamp":1765549702008},"postHourTrading":{"tag":"盘后","latestPrice":7.21,"preClose":7.17,"latestTime":"19:58 EST","volume":371392,"amount":2662889.251,"timestamp":1765587482193},"volumeRatio":0.6852014005744961,"impliedVol":0.681,"impliedVolPercentile":0.236},"requestUrl":"/m/hq/s/XERS","defaultTab":"news","newsList":[{"id":"2590328286","title":"Xeris Biopharma Initiated at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2590328286","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590328286?lang=en_us&edition=fundamental","pubTime":"2025-12-10 00:38","pubTimestamp":1765298280,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/XERS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 09, 2025 11:38 ET (16:38 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2590495203","title":"Barclays Initiates Xeris Biopharma Holdings at Overweight With $9 Price Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2590495203","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590495203?lang=en_us&edition=fundamental","pubTime":"2025-12-09 21:06","pubTimestamp":1765285564,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (XERS) has an average rating of buy and mean price target of $11.14, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2588061642","title":"Xeris Biopharma Officer Beth Hecht Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2588061642","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588061642?lang=en_us&edition=fundamental","pubTime":"2025-12-03 06:14","pubTimestamp":1764713691,"startTime":"0","endTime":"0","summary":"Beth Hecht, an officer at Xeris Biopharma Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL6FZc7Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Officer Beth Hecht Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2588722393","title":"Xeris Biopharma Holdings Inc - Unit Receives Uspto Notice of Allowance for XP-8121 Patent","url":"https://stock-news.laohu8.com/highlight/detail?id=2588722393","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588722393?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:08","pubTimestamp":1764590908,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nFWN3X70P5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2588724036","title":"Xeris Biopharma Receives Notice of Allowance from USPTO for XP-8121 Patent Application","url":"https://stock-news.laohu8.com/highlight/detail?id=2588724036","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588724036?lang=en_us&edition=fundamental","pubTime":"2025-12-01 20:01","pubTimestamp":1764590475,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for its patent application covering XP-8121, a novel product candidate. The allowed claims are specific to the XP-8121 formulation. The patent is expected to be issued following standard administrative steps. Xeris is also pursuing additional intellectual property protection related to levothyroxine technology.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire  on December 01, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nNDL5hLKSX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2584926252","title":"Xeris Biopharma Q3 Net Income USD 621 Thousand","url":"https://stock-news.laohu8.com/highlight/detail?id=2584926252","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584926252?lang=en_us&edition=fundamental","pubTime":"2025-11-20 00:52","pubTimestamp":1763571139,"startTime":"0","endTime":"0","summary":"Nov 06 (Reuters) - Xeris Biopharma Q3 EPS USD 0.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 06-NOV-202511:00:00.293 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD8RCXxK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2584670975","title":"Xeris Biopharma Holdings Inc. Director and Officer John Patrick Shannon Jr. Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584670975","media":"Reuters","labels":["insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584670975?lang=en_us&edition=fundamental","pubTime":"2025-11-18 06:59","pubTimestamp":1763420371,"startTime":"0","endTime":"0","summary":"John Patrick Shannon Jr., Director and Officer at Xeris Biopharma Holdings Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL9t66vd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Holdings Inc. Director and Officer John Patrick Shannon Jr. Reports Disposal of Common Shares","news_tag":"insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2584696406","title":"Xeris Biopharma (XERS): Valuation Insights After New Recorlev Patent, Profit Boost, and 2025 Outlook Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2584696406","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584696406?lang=en_us&edition=fundamental","pubTime":"2025-11-17 03:22","pubTimestamp":1763320941,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings (XERS) just reported an impressive quarter, swinging to a profit alongside strong revenue growth and raising its outlook for 2025. The company also secured a new patent for its Recorlev treatment, which extends protection against future generics.\nSee our latest analysis for Xeris Biopharma Holdings.\nAfter a stellar year, Xeris Biopharma’s recent quarter added to the momentum, as improving fundamentals and a new patent gave investors plenty to cheer about. Despite last...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/xeris-biopharma-xers-valuation-insights-after-new-recorlev-p","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xers/xeris-biopharma-holdings/news/xeris-biopharma-xers-valuation-insights-after-new-recorlev-p","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["XERS"],"gpt_icon":0},{"id":"2583451475","title":"Xeris Biopharma Holdings Inc. Officer Beth Hecht Reports Disposal of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583451475","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583451475?lang=en_us&edition=fundamental","pubTime":"2025-11-14 08:00","pubTimestamp":1763078409,"startTime":"0","endTime":"0","summary":"Beth Hecht, an officer of Xeris Biopharma Holdings Inc., has reported a disposal of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251114:nNDL1DVDmL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Xeris Biopharma Holdings Inc. Officer Beth Hecht Reports Disposal of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2583573531","title":"Xeris Biopharma Holdings Inc : Leerink Partners Raises Target Price to $11 From $9","url":"https://stock-news.laohu8.com/highlight/detail?id=2583573531","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583573531?lang=en_us&edition=fundamental","pubTime":"2025-11-13 11:59","pubTimestamp":1763006377,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nFWN3WO1H6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2581887445","title":"Craig-Hallum Remains a Buy on Xeris Pharmaceuticals (XERS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581887445","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581887445?lang=en_us&edition=fundamental","pubTime":"2025-11-08 00:37","pubTimestamp":1762533442,"startTime":"0","endTime":"0","summary":"In a report released today, Chase Knickerbocker from Craig-Hallum maintained a Buy rating on Xeris Pharmaceuticals, with a price target of $12.00. ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-xeris-pharmaceuticals-xers-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/craig-hallum-remains-a-buy-on-xeris-pharmaceuticals-xers-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","XERS"],"gpt_icon":0},{"id":"2581500241","title":"Xeris Biopharma price target raised to $8 from $6 at Piper Sandler","url":"https://stock-news.laohu8.com/highlight/detail?id=2581500241","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581500241?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:55","pubTimestamp":1762516551,"startTime":"0","endTime":"0","summary":"Piper Sandler analyst David Amsellem raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $6 and keeps a Neutral rating on the share...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-8-from-6-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xeris-biopharma-price-target-raised-to-8-from-6-at-piper-sandler-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"2581567019","title":"Xeris Biopharma Down Over 21%, On Pace for Largest Percent Decrease Since June 2020 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2581567019","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581567019?lang=en_us&edition=fundamental","pubTime":"2025-11-07 02:33","pubTimestamp":1762453980,"startTime":"0","endTime":"0","summary":"Xeris Biopharma Holdings, Inc.  is currently at $7.78, down $2.10 or 21.23%. --Would be lowest close since Sept. 19, 2025, when it closed at $7.72. --On pace for largest percent decrease since June 25, 2020, when it fell 48.78%. --Currently down two consecutive days; down 21.46% over this period. --Up 129.35% year-to-date; on pace for best year on record . --Down 71.45% from its all-time closing high of $27.23 on Sept. 10, 2018. --Up 131.4% from 52 weeks ago , when it closed at $3.36. --Traded as low as $7.76; lowest intraday level since Sept. 25, 2025, when it hit $7.72. --Down 21.43% at today's intraday low; largest intraday percent decrease since March 6, 2024, when it fell as much as 21.43%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS","BK4007"],"gpt_icon":0},{"id":"1181372012","title":"Stock Track | Xeris Pharmaceuticals Plunges 16.41% Despite First-Ever Quarterly Profit as Revenue Guidance Disappoints","url":"https://stock-news.laohu8.com/highlight/detail?id=1181372012","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181372012?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:41","pubTimestamp":1762443667,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals Inc (XERS) shares plummeted 16.41% in Thursday's trading session, despite the company reporting its first-ever quarterly net income. The sharp decline came as investors reacted...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"1120616184","title":"Stock Track | Xeris Pharmaceuticals Plummets 16.41% After Q3 Revenue Miss and Lowered 2025 Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1120616184","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120616184?lang=en_us&edition=fundamental","pubTime":"2025-11-06 23:41","pubTimestamp":1762443661,"startTime":"0","endTime":"0","summary":"Shares of Xeris Pharmaceuticals Inc (XERS) plunged 16.41% in early trading on Thursday, following the company's third-quarter earnings report that fell short of expectations and a downward revision...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"1125025877","title":"Xeris Biopharma Q3 2025 Earnings Call Summary and Q&A Highlights: Record Revenue and Strategic Expansion","url":"https://stock-news.laohu8.com/highlight/detail?id=1125025877","media":"Earnings Call","labels":["earningsCall"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125025877?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:21","pubTimestamp":1762438894,"startTime":"0","endTime":"0","summary":"[Management View]Xeris Biopharma reported a record net product revenue of $74.1 million for Q3 2025, marking a 40% year-over-year increase. The growth was driven by strong performance across all...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"earningsCall","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XERS"],"gpt_icon":0},{"id":"2581091672","title":"Xeris Biopharma (XERS) Q3 2025 Earnings Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2581091672","media":"Motley Fool Transcribing","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581091672?lang=en_us&edition=fundamental","pubTime":"2025-11-06 22:16","pubTimestamp":1762438595,"startTime":"0","endTime":"0","summary":"DateThursday, Nov. 6, 2025 at 8:30 a.m. ETCall participantsChief Executive Officer — John P. ShannonChief Financial Officer — Steven M. PieperNeed a quote from a Motley Fool analyst?","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_motley_transcript","url":"https://www.fool.com/earnings/call-transcripts/2025/11/06/xeris-biopharma-xers-q3-2025-earnings-transcript/","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/earnings/call-transcripts/2025/11/06/xeris-biopharma-xers-q3-2025-earnings-transcript/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_motley_transcript","symbols":["XERS"],"gpt_icon":0},{"id":"2581060520","title":"Earnings Flash (XERS) Xeris Biopharma Posts Q3 EPS $0, vs. FactSet Est of $0","url":"https://stock-news.laohu8.com/highlight/detail?id=2581060520","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581060520?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:31","pubTimestamp":1762432294,"startTime":"0","endTime":"0","summary":"Earnings Flash (XERS) Xeris Biopharma Posts Q3 EPS $0, vs. FactSet Est of $0","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XERS"],"gpt_icon":0},{"id":"1113153563","title":"Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market Following Q3 Earnings and Revenue Guidance Update","url":"https://stock-news.laohu8.com/highlight/detail?id=1113153563","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1113153563?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:06","pubTimestamp":1762430807,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals Inc (XERS) saw its stock price plummet 6.79% in pre-market trading on Thursday, following the release of its third-quarter earnings report and an update to its revenue guidance...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0},{"id":"1156774454","title":"Stock Track | Xeris Pharmaceuticals Plunges 6.79% Pre-market on Q3 Revenue Miss and Updated Guidance","url":"https://stock-news.laohu8.com/highlight/detail?id=1156774454","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1156774454?lang=en_us&edition=fundamental","pubTime":"2025-11-06 20:06","pubTimestamp":1762430803,"startTime":"0","endTime":"0","summary":"Xeris Pharmaceuticals Inc (XERS) shares tumbled 6.79% in pre-market trading on Thursday, as investors reacted to the company's third-quarter earnings report and updated revenue guidance for 2025....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["XERS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.xerispharma.com","stockEarnings":[{"period":"1week","weight":0.1014},{"period":"1month","weight":-0.0553},{"period":"3month","weight":-0.0427},{"period":"6month","weight":0.6483},{"period":"1year","weight":1.1088},{"period":"ytd","weight":1.115}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":-0.071149},{"month":2,"riseRate":0.714286,"avgChangeRate":-0.011486},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.030403},{"month":4,"riseRate":0.428571,"avgChangeRate":0.030526},{"month":5,"riseRate":0.714286,"avgChangeRate":0.17169},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.067395},{"month":7,"riseRate":0.5,"avgChangeRate":-0.009808},{"month":8,"riseRate":0.625,"avgChangeRate":0.207997},{"month":9,"riseRate":0.375,"avgChangeRate":-0.064053},{"month":10,"riseRate":0.5,"avgChangeRate":-0.004147},{"month":11,"riseRate":0.5,"avgChangeRate":-0.025098},{"month":12,"riseRate":0.5,"avgChangeRate":0.039874}],"exchange":"NASDAQ","name":"Xeris Pharmaceuticals Inc","nameEN":"Xeris Pharmaceuticals Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Xeris Pharmaceuticals Inc,XERS,Xeris Pharmaceuticals Inc股票,Xeris Pharmaceuticals Inc股票老虎,Xeris Pharmaceuticals Inc股票老虎国际,Xeris Pharmaceuticals Inc行情,Xeris Pharmaceuticals Inc股票行情,Xeris Pharmaceuticals Inc股价,Xeris Pharmaceuticals Inc股市,Xeris Pharmaceuticals Inc股票价格,Xeris Pharmaceuticals Inc股票交易,Xeris Pharmaceuticals Inc股票购买,Xeris Pharmaceuticals Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Xeris Pharmaceuticals Inc(XERS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Xeris Pharmaceuticals Inc(XERS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}